Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions-Reference-Cited by-同舟云学术

Expression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesions

Published:2017-02-27 Issue:1 Volume:17 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Inari Hitoshi,Suganuma Nobuyasu,Kawachi Kae,Yoshida Tatsuya,Yamanaka Takashi,Nakamura Yoshiyasu,Yoshihara Mitsuyo,Nakayama Hirotaka,Yamanaka Ayumi,Masudo Katsuhiko,Oshima Takashi,Yokose Tomoyuki,Rino Yasushi,Shimizu Satoru,Miyagi Yohei,Masuda Munetaka

Funder

the Platform of Supporting Cohort Study and Biospecimen Analysis

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s12885-017-3154-3.pdf

Reference39 articles.

1. Kobayashi T. From improved survival to potential cure in patients with metastatic breast cancer. Breast Cancer. 2012;19(3):187–90. doi: 10.1007/s12282-011-0307-0 .

2. Hortobagyi GN. Can we cure limited metastatic breast cancer? J Clin Oncol. 2002;20(3):620–3.

3. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol. 1996;14(8):2197–205.